Vipoma clinical trials

The registry lists 23 studies for Vipoma across more than 10 countries. 0 are recruiting or about to start. 1 of them are mainly about Vipoma (how this is decided). Per ClinicalTrials.gov, last updated 2026-05-12.

Status

Completed: 15
Terminated: 3
Withdrawn: 3
Active, not recruiting: 1
Status unknown: 1

Phase

Phase 2: 13
Phase 1: 7
Phase 3: 2

Where

United States: 17
Canada: 3
Sweden: 1
Greece: 1
Italy: 1
Poland: 1

Who runs them

National Cancer Institute (NCI) (6) · British Columbia Cancer Agency (2) · Vanderbilt-Ingram Cancer Center (2) · Novartis Pharmaceuticals (2) · Memorial Sloan Kettering Cancer Center (2) · Eastern Cooperative Oncology Group (2) · Laser Tissue Welding, Inc. (1) · Columbia University (1)

What is being tested here

Drugs under test in Vipoma studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Octreotide	0	0	3
Capecitabine	0	0	2
Temozolomide	0	0	2
Motesanib diphosphate	0	0	1
Everolimus	0	0	1
Epothilone B	0	0	1
Fluorouracil	0	0	1
Irinotecan	0	0	1
Leucovorin	0	0	1
Sorafenib	0	0	1

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 4 · Antimetabolites 4 · Alkylating agents 3

Who these studies take

No Vipoma study is recruiting now.

Across all 23 studies, recruiting or not: 0% stop at 75 or younger and 0% at 65; 9% take children; 0% are for women only and 0% for men only; 0% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

Studies

Recruiting first, then most recently updated. Showing 23 of 23. search them.